http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 14:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Jun+05++Filed+by%3A+Pershing+Edward/26610632.html si-local-file:///var/storage/secattach/20260605/26610632.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Jun+05++Filed+by%3A+Pershing+Edward/26610632.html Fri, 05 Jun 2026 14:58:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Jun+05++Filed+by%3A+Pershing+Edward/26610632.html si-local-file:///var/storage/secattach/20260605/26610632.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Jun+05++Filed+by%3A+Pershing+Edward/26610632.html Fri, 05 Jun 2026 14:58:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+28++Filed+by%3A+Pershing+Edward/26572917.html si-local-file:///var/storage/secattach/20260529/26572917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+28++Filed+by%3A+Pershing+Edward/26572917.html Fri, 29 May 2026 13:22:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+28++Filed+by%3A+Pershing+Edward/26572917.html si-local-file:///var/storage/secattach/20260529/26572917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+28++Filed+by%3A+Pershing+Edward/26572917.html Fri, 29 May 2026 13:22:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+23++Filed+by%3A+Pershing+Edward/26547640.html si-local-file:///var/storage/secattach/20260526/26547640.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+23++Filed+by%3A+Pershing+Edward/26547640.html Tue, 26 May 2026 10:57:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+23++Filed+by%3A+Pershing+Edward/26547640.html si-local-file:///var/storage/secattach/20260526/26547640.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+23++Filed+by%3A+Pershing+Edward/26547640.html Tue, 26 May 2026 10:57:00 -0400 O.01130034 PVCT http://www.streetinsider.com/Corporate+News/Provectus+reports+oral+PV-10+shows+anti-tumor+activity+in+bladder+cancer+study/26510543.html <p>Provectus Biopharmaceuticals Inc. (OTCQB: PVCT) announced results from a preclinical study evaluating oral and intravesical administration of PV-10, its rose bengal sodium formulation, in a bladder cancer model. The study was conducted by Translational Drug Development, LLC using immunologically humanized mice with orthotopic bladder tumors.</p><p>The seven-arm study tested different treatment approaches over 45 days using 54 female mice. Oral PV-10 monotherapy ranked highest in the company's scoring framework, which assessed anti-tumor response, survival, safety, data quality, and translational potential.</p><p>Two animals treated with oral PV-10 survived to study completion and showed no gross bladder tumor at necropsy examination. One survivor came http://www.streetinsider.com/Corporate+News/Provectus+reports+oral+PV-10+shows+anti-tumor+activity+in+bladder+cancer+study/26510543.html Mon, 18 May 2026 08:02:26 -0400 PVCT http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Press+Releases/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html <ul type="disc"><li>Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal.<br/><br/></li></ul> <p align="justify"><strong>KNOXVILLE, Tenn., May 18, 2026 (GLOBE NEWSWIRE) -- </strong><b>Provectus Biopharmaceuticals, Inc.</b> (“Provectus” or the “Company”) (OTCQB: PVCT) today reported data from a preclinical safety and efficacy evaluation of PV-10 — a formulation of the Company’s proprietary, pharmaceutical-grade rose bengal sodium (RBS) active pharmaceutical ingredient — administered by oral and intravesical routes as a single agent and in combination with anti-human PD-1 against an orthotopic bladder carcinoma tumor http://www.streetinsider.com/Globe+Newswire/Provectus+Biopharmaceuticals+Reports+Oral+PV-10+Anti-Tumor+Activity+in+Preclinical+Bladder+Cancer+Study%3B+Long-Term+Survivors+Show+Absence+of+Gross+Bladder+Tumor+at+Study+End/26510508.html Mon, 18 May 2026 08:00:00 -0400 A.50200982 O.00081842 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+15++Filed+by%3A+Pershing+Edward/26502439.html si-local-file:///var/storage/secattach/20260515/26502439.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+15++Filed+by%3A+Pershing+Edward/26502439.html Fri, 15 May 2026 11:54:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+15++Filed+by%3A+Pershing+Edward/26502439.html si-local-file:///var/storage/secattach/20260515/26502439.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+15++Filed+by%3A+Pershing+Edward/26502439.html Fri, 15 May 2026 11:54:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Mar+31/26493349.html si-local-file:///var/storage/secattach/20260514/26493349.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Mar+31/26493349.html Thu, 14 May 2026 13:52:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Mar+31/26493349.html si-local-file:///var/storage/secattach/20260514/26493349.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Mar+31/26493349.html Thu, 14 May 2026 13:52:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+07++Filed+by%3A+Pershing+Edward/26451327.html si-local-file:///var/storage/secattach/20260507/26451327.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+07++Filed+by%3A+Pershing+Edward/26451327.html Thu, 07 May 2026 12:24:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+07++Filed+by%3A+Pershing+Edward/26451327.html si-local-file:///var/storage/secattach/20260507/26451327.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+May+07++Filed+by%3A+Pershing+Edward/26451327.html Thu, 07 May 2026 12:24:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Dec+31/26403670.html si-local-file:///var/storage/secattach/20260430/26403670.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Dec+31/26403670.html Thu, 30 Apr 2026 11:13:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Dec+31/26403670.html si-local-file:///var/storage/secattach/20260430/26403670.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++PROVECTUS+BIOPHARMACEUTI++For%3A+Dec+31/26403670.html Thu, 30 Apr 2026 11:13:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PROVECTUS+BIOPHARMACEUTI+++++++++++++/26403627.html si-local-file:///var/storage/secattach/20260430/26403627.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PROVECTUS+BIOPHARMACEUTI+++++++++++++/26403627.html Thu, 30 Apr 2026 11:09:00 -0400 O.01130034 PVCT http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PROVECTUS+BIOPHARMACEUTI+++++++++++++/26403627.html si-local-file:///var/storage/secattach/20260430/26403627.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++PROVECTUS+BIOPHARMACEUTI+++++++++++++/26403627.html Thu, 30 Apr 2026 11:09:00 -0400 O.01130034 PVCT